What is Vesicare (solifenacin) used for?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Vesicare Used For?

Vesicare (solifenacin) is a muscarinic antagonist medication used to treat overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. 1

Primary Indication

Solifenacin is FDA-approved specifically for treating adults with overactive bladder syndrome who experience: 1

  • Urge urinary incontinence: involuntary leaking or wetting accidents accompanied by a strong, sudden need to urinate 1
  • Urgency: a strong, immediate need to urinate that is difficult to defer 1
  • Urinary frequency: urinating too often throughout the day 1

Position in Treatment Algorithm

Solifenacin is recommended as second-line therapy for overactive bladder, to be initiated only after behavioral therapies have been tried. 2 The American Urological Association guidelines establish that behavioral interventions—including bladder training, delayed voiding, pelvic floor muscle training, fluid management, and weight loss—should be attempted first. 3

Clinical Efficacy

Solifenacin demonstrates effectiveness across all overactive bladder symptoms: 2

  • Reduces urinary incontinence episodes 2
  • Decreases urgency episodes 2
  • Reduces urinary frequency 2
  • Improves nocturia (nighttime urination) 2

The medication shows dose-response effects, with both 5 mg and 10 mg doses demonstrating symptom improvement compared to placebo, though the absolute benefit is modest (less than 20% absolute risk difference). 4

Combination Therapy Options

For patients with inadequate response to monotherapy, solifenacin can be combined with: 5, 2

  • Mirabegron 50 mg: The combination of solifenacin 5 mg plus mirabegron 50 mg demonstrates superior efficacy to either medication alone in reducing incontinence episodes and urination frequency, per European Association of Urology guidelines 2
  • Tamsulosin: For men with both storage and voiding lower urinary tract symptoms 5
  • β3-adrenoceptor agonists: For patients refractory to monotherapy 5

Important Safety Considerations

Solifenacin is contraindicated in patients who: 1

  • Cannot empty their bladder (urinary retention) 1
  • Have delayed or slow gastric emptying (gastric retention) 1
  • Have uncontrolled narrow-angle glaucoma 1
  • Are allergic to solifenacin or its ingredients 1

Use with extreme caution in patients with: 2

  • Impaired gastric emptying 2
  • History of urinary retention 2
  • Narrow-angle glaucoma 2

Common Adverse Effects

The most frequently reported side effects include: 1

  • Dry mouth (21.4% of patients) 6
  • Constipation (13.3% of patients) 6
  • Blurred vision 1
  • Urinary tract infection 1

These anticholinergic effects are generally mild to moderate in severity, though approximately 10% of patients discontinue treatment due to adverse events. 6

Age Considerations

Solifenacin is equally well tolerated in younger (≤65 years) and older (>65 years) patients, with similar incidence and severity of adverse effects across age groups. 7 However, beta-3 agonists like vibegron may be preferable for elderly patients due to lower risk of cognitive impairment or dementia compared to antimuscarinic medications. 3

References

Guideline

Solifenacin for Overactive Bladder Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Overactive Bladder Treatment with Gemtesa (Vibegron)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Solifenacin for Overactive Bladder Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.